24 results
Thumbnail

D3.100 - Assessment of the impact of psychotropic drugs, antihistamines, and corticosteroids on the interpretation of skin tests in allergology

Thumbnail

D3.101 - Etoricoxib Associated Fixed Drug Eruption: A Case Series from a Tertiary Allergy and Clinical Immunology Centre, United Arab Emirates

Thumbnail

D3.93 - Clinical Efficacy of Tezepelumab in a Patient with Severe Refractory Mixed Asthma: A Case Report from Kazakhstan

Thumbnail

D3.106 - Real-life outcomes of rapid drug desensitization to taxanes

Thumbnail

D3.94 - Good Practice Recommendations for Basophil Activation Test (BAT) Data Analysis in Routine and High-Background Settings

Thumbnail

D3.95 - Hidden in everyday cosmetics: Facial allergic contact dermatitis to fragrances

Thumbnail

D3.96 - High burden of latent aeroallergen sensitization in healthy urban medical students: a blinded skin prick test study from South India

Thumbnail

D3.97 - Allergic contact dermatitis confirmed by repeated open application test in a 68‑year‑old patient

Thumbnail

D3.98 - An extended study for the multiple detection of IgE-mediated allergic reactions using microarray technology

Thumbnail

D3.104 - Molecular Co-Sensitization Mapping Using a 192-Line Multiplex IgE Platform

Thumbnail

D3.105 - Analysis of post-vaccination immunity in children with dermatology diseases receiving biologic and immunosuppressive therapy

Thumbnail

D3.107 - Comparison of Cupressaceae sensitization allergens in a large Spanish cohort

Thumbnail

D3.103 - Comprehensive Allergen Characterization for Standardized Basophil Activation Testing

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial